Orlistat Market – 2021 Application Scope, Types, Technology Benefits and Global Business Outlook By Coherent Market Insights

SEATTLE, April 08, 2021, (PHARMIWEB) — Orlistat is a gastrointestinal lipase inhibitor, which blocks 25% absorption of fat in meal and is indicated for the treatment of obesity or overweight. This lipase inhibitors reduce the calorie intake. The primary function of orlistat is to inhibit pancreatic and gastric lipases along with pancreatic and gastric enzymes breakdown triglycerides in the intestine. The tryglycerides from the diet remain unchanged when activity of lipase is blocked. Moreover, orlistat assists in reducing blood pressure and prevents the inception of type 2 diabetes in obese people. Orlistat medication does not let one to regain lost weight and does not block the absorption of fats from non-fat foods and sugar.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1878

Global Orlistat Market Dynamics- Drivers

Growing awareness campaigns regarding weight management is expected to drive growth of the global orlistat market during the forecast period. For instance, in 2013, Roche Holding AG, a pharmaceutical company, launched its new campaign ‘New You Weight Consciousness Advocacy Campaign’, which was intended to increase awareness among the populace regarding obesity and its treatment options. Thus, such awareness campaigns are expected boost the adoption of weight management medication treatments, which in turn, is expected to propel growth of the global orlistat market size.

Key products in the market are adopting market strategies such as collaborations and partnerships to re-launch their products, which is expected to boost the market in the near future. For instance, in February 2018, H2 Pharma, LLC partnered with Cheplapharma Arzneimittel GmbH and re-launched Xenical Capsules, which was acquired from F.Hoffman-La Roche. Xenical capsules were re-launched to increase awareness regarding medication related to weight management, this in turn, is expected to boost orlistat market growth.

Moreover, robust medications pipeline by key market players is expected to boost the market growth over the forecast period. For instance, orlistat by University of Texas South Western Medical center is in phase 2 since 2015. Orlistat is used for the treatment of hyperlipoproteinemia type 1. Hyperlipoproteinemia type 1 is caused due to deficiency of lipoprotein lipase. SLx-4090 by University of Texas South Western Medical center is in phase 2 to study its effectiveness in combination with Orlistat. SLx-4090 is used to treat high blood fat level mostly observed in hyperlipoproteinemia type 1 patients.

Growing prevalence of obesity is expected to boost the global orlistat market growth. According to National Family Health Survey, 2015, in India, over 9.8 million men and over 20 million women were recorded to be obese. According to the same souce, India stands as the second-highest in the world for obese children, with the number constantly increasing by 3-5 million patients every year.

Global Orlistat Market Dynamics- Restraints

Availability of alternate methods such as devices that reduce fat is expected to hinder the global orlistat market growth in the near future. For instance, Ultra shape fat melting device helps remove body fat using pulsed ultrasound waves that neither use heat nor cold to remove body fat.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1878

Regional Insights

Among regions, North America is expected to hold a dominant position in the global orlistat market during the forecast period. This is owing to high prevalence of obesity in the region. According to National Institute of Health’s study, in 2016, over 38% of adults aged 20 years and above were obese, over 17.2% of children aged 7 years and above were obese, and over 30% of the population is considered to be overweight in the U.S. According to World Health Organization (WHO)’s study, in 2015, over 40 million children aged 5 years and above were overweight in the U.S. Thus, high prevalence of obesity is expected to fuel North America Orlistat market growth over the forecast period.

Europe Orlistat market is expected to witness significant growth during the forecast period, owing to increasing launch of new generic version of Orlistat in the region. For instance, in 2011, Teva Pharmaceutical Industries Ltd. introduced generic version of Xenical Capsules in the U.K., which was manufactured by Roche Holding AG. Xenical Capsules is used for the treatment of obesity as well as for those whose BMI is greater than or equal to 30kg/m² and overweight patients. Since the drug is more affordable than patented versions, it is expected drive orlistat market growth in the region.

Global Orlistat Market- Competitive Landscape

Key players operating in the Global orlistat market include Roche Holding AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd, Sandoz Pharmaceuticals, STADA–VN J.V. Co., Ltd., Hexal AG., National Company for Pharmaceutical Industry, Lunan Pharmaceutical group Corporation Ltd., ZEIN Pharmaceutical Co. Ltd., HISUN Pharmaceuticals Co. Ltd., Taj Pharmaceuticals Ltd., D.M. Pharma, China Zhongshan Pharma Co. Ltd., and Kabir Life Sciences and Research Pvt. Ltd.

Global Orlistat Market Taxonomy:-

The global orlistat market is segmented based on distribution channel and region:

By Distribution channel:-

• Hospitals/Clinics
• Online Pharmacies
• Retail Pharmacies

By Region:-

• North America
• Europe
• Latin America
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837